SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a medical‑stage pharmaceutical firm centered on modulating lipid‑signaling pathways to develop therapies for individuals dwelling with most cancers, ache, dermatological, or neurological circumstances, in the present day introduced that it has obtained a letter from The Nasdaq Inventory Market LLC (“Nasdaq”) confirming that the Firm has regained compliance with Nasdaq Itemizing Rule 5550(b)(1), the “Equity Rule,” and Itemizing Rule 5620(a), the “Annual Shareholders Meeting Rule.”
Nasdaq additional confirmed that, primarily based on the Firm’s Kind 8-Ok filed January 30, 2026, the Firm held its reconvened annual assembly on that date and, primarily based on the Firm’s Kind 8-Ok filed March 30, 2026, the Firm regained compliance with the Fairness Rule. In accordance with Nasdaq Itemizing Rule 5815(d)(4)(B), the Firm will likely be topic to a compulsory panel monitor for a interval of 1 12 months from the date of the letter.
“We are pleased to have regained compliance with Nasdaq’s continued listing requirements,” mentioned Gregory D. Gorgas, President and Chief Govt Officer of Artelo Biosciences. “With this matter behind us, we remain focused on disciplined execution across our portfolio, including progressing potential partnership negotiations with ART27.13 boosted by the encouraging Phase 2 CAReS interim data suggesting its potential for mitigating or reversing the effects of cancer anorexia-cachexia syndrome.”
ART27.13 can also be below investigation in an externally funded Section 2 research as an orally administered agent for the remedy of glaucoma. Artelo’s second medical stage investigational drug and the primary product candidate derived from our FABP5 inhibitor platform, ART26.12 is advancing as a non-opioid and non-scheduled drug for the remedy of neuropathic ache.
“As we continue to advance our pipeline with a focus on high-value indications and capital-efficient development, we believe Artelo is well-positioned to unlock meaningful long-term value for shareholders,” added Gorgas
More Read
About Artelo Biosciences
Ahead Wanting Statements
This press launch accommodates sure forward-looking statements throughout the which means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934, as amended, together with statements relating to the Firm’s plans and expectations. These statements contain identified and unknown dangers, uncertainties, and different components which will trigger precise outcomes to vary materially from these expressed or implied by such statements, together with market and different circumstances. All statements that aren’t historic info are forward-looking statements, together with however not restricted to, statements relating to: using proceeds from the providing and the potential train of the warrants. For a dialogue of dangers and uncertainties, please check with the Firm’s filings with the Securities and Change Fee, together with its most up-to-date Annual Report on Kind 10-Ok. The Firm undertakes no obligation to publicly replace any forward-looking assertion, besides as required by relevant securities legal guidelines.
More Read
